El interés en corto de Molina Healthcare da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Molina Healthcare. Los datos de interés en corto se actualizan cada dos semanas.

Molina Healthcare (NYSE:MOH) Bolsa, Informe de interés en corto

MOLINA HEALTHCARE INC

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

Kuala,Lumpur,,Malaysia,-,November,08,,2023:,Makeup,Products,On

Equities

News

Markets

BABA

BIDU

NVDA

OSCR

Citigourp Global Markets 2% Protected Notes Linked To The Djia

El inversor Michael Burry duplica su participación en Estée Lauder mientras reduce posiciones en NVIDIA y empresas tecnológicas chinas.

Michael Burry apuesta por Estée Lauder (EL) mientras reduce posiciones en tecnología

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

Collaborative Investment Series Trust Mohr Growth ETF

Mohawk Industries Inc

Health insurer Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) is scheduled to release its second quarter 2025 financial <a href="https://www.benzinga.com/pressreleases/25/07/b46233308/elevance-health-to-hold-conference-call-and-webcast-to-discuss-second-quarter-2025-results-on-july" target="_blank" rel="noreferrer noopener">results on July 17</a>.
Analysts estimate adjusted earnings of $9.197 per share on sales of $48.24 billion, <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has been the first major health insurer to report quarterly earnings for several quarters. However, this quarter, the insurance giant will release its second quarter 2025 financial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45734284/unitedhealth-group-announces-earnings-release-date" rel="noreferrer noopener">results on July 29</a>.
As it&#8217;s the biggest player in the industry, Forbes writes that analysts and investors often use its results to gauge the sector&#8217;s overall health.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280387/unitedhealth-centene-hit-hard-by-guidance-shock-trumps-medicaid-push" target="_blank" rel="noreferrer noopener">UnitedHealth, Centene Hit Hard By Guidance Shock, Trump&#8217;s Medicaid Push</a>
All eyes will be on the sector after Centene Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) withdrawal of its 2025 GAAP and adjusted diluted EPS guidance, which stems from its initial review of 2025 industry data from Wakely, an <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" rel="noreferrer noopener">independent actuarial firm</a>.
While withdrawing its comprehensive EPS guidance, Centene has reaffirmed its&nbsp;fiscal year 2025 adjusted EPS&nbsp;to be greater than $7.25, aligning with the consensus of $7.23.
UnitedHealth suspended its 2025 outlook in May, citing that care activity <a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">continued to accelerate</a>.
Earlier in July, managed healthcare service provider under the Medicaid and Medicare programs, Molina Healthcare, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), issued preliminary second-quarter results and lowered its full-year 2025 earnings outlook, citing rising medical costs across its Medicaid, Medicare,&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance" rel="noreferrer noopener">and state marketplace businesses</a>.
The company expects Q2 adjusted earnings of approximately $5.50 per share—slightly below earlier forecasts—due to expected cost pressures that will persist into the second half of the year.
As a result, Molina cut its full-year 2025 adjusted EPS guidance to $21.50 -$22.50, down from at&nbsp;least $24.50&nbsp;previously. The new forecast reflects a consolidated pre-tax margin just under 4%, at the low end of the company&#8217;s long-term target.
Forbes <a target="_blank" href="https://www.forbes.com/sites/brucejapsen/2025/07/14/eyes-on-elevance-health-not-unitedhealth-as-first-to-report-earnings/" rel="noreferrer noopener">adds</a> Centene&#8217;s announcement is just the latest in a series of updates from health insurers who, over the past two years, have had a hard time managing the costs of people enrolled in government-subsidized health plans.
Price Action: UNH stock is down 1.29% at $300.19 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46394267/why-is-workhorse-stock-tumbling-on-monday" target="_blank" rel="noreferrer noopener">Workhorse Stock Tanks On Merger Talks With Private EV Maker</a></li>
</ul>
Image: Shutterstock

Earnings

Large Cap

Health Care

Movers

Trading Ideas

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 5.43% on an annualized basis producing an average annual return of 17.79%. Currently, Molina Healthcare has a market capitalization of $11.94 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $11,482.97 today based on a price of $220.32 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752502512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Molina Healthcare 15 Years Ago Would Be Worth Today

Mizuho analyst Ann Hynes maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Outperform and lowers the price target from $400 to $330.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Molina Healthcare, Lowers Price Target to $330

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wells Fargo analyst Timur Braziler downgraded Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) from Overweight to Equal-Weight and lowered the price target from $29 to $27. Columbia Banking System shares closed at $25.07 on Wednesday. <a href="https://www.benzinga.com/quote/colb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Erin Wright downgraded Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) from Overweight to Equal-Weight and lowered the price target from $364 to $266. Molina Healthcare shares closed at $237.22 on Wednesday. <a href="https://www.benzinga.com/quote/moh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Christine Cho downgraded the rating for The Cheesecake Factory Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) from Buy to Neutral but raised the price target from $66 to $67. Cheesecake Factory shares closed at $64.14 on Wednesday. <a href="https://www.benzinga.com/quote/vake/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Gautam Khanna downgraded Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) from Buy to Hold and cut the price target from $500 to $480. Lockheed Martin shares closed at $463.06 on Wednesday. <a href="https://www.benzinga.com/quote/lmt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Mike Colonnese downgraded the rating for Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from Buy to Sell and slashed the price target from $305 to $300. Coinbase Global shares closed at $373.85 on Wednesday. <a href="https://www.benzinga.com/quote/coin/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying COIN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/COIN/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10101039/image-120-1024x603.png" alt="" class="wp-image-980194" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10101039/image-120-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10101039/image-120-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10101039/image-120-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10101039/image-120.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a> </li>
</ul>
Photo via Shutterstock

Downgrades

CAKE

COIN

COLB

This Coinbase Global Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $354.14, a high estimate of $414.00, and a low estimate of $266.00. This upward trend is apparent, with the current average reflecting a 1.36% increase from the previous average price target of $349.40.
<img src="https://www.benzinga.com/files/images/story/2025/1752156035_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Molina Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$266.00</td>
<td>$364.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$347.00</td>
<td>$351.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$364.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$351.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$362.00</td>
<td>$339.00</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$414.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$375.00</td>
<td>$331.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Molina Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Molina Healthcare's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Molina Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Delving into Molina Healthcare's Background</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Molina Healthcare's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 12.24%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Molina Healthcare's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.67%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.77% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Molina Healthcare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.86%, the company showcases efficient use of assets and strong financial health.
Debt Management: Molina Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.87.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Molina Healthcare In The Eyes Of 7 Experts

Morgan Stanley analyst Erin Wright downgrades Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) from Overweight to Equal-Weight and lowers the price target from $364 to $266.

Morgan Stanley Downgrades Molina Healthcare to Equal-Weight, Lowers Price Target to $266

Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) on Monday issued preliminary second-quarter results and lowered its full-year 2025 earnings outlook, citing rising medical costs across its Medicaid, Medicare, <a href="https://www.benzinga.com/topic/medicare">and state marketplace businesses</a>.
The managed care company now expects Q2 adjusted earnings of approximately $5.50 per share—slightly below earlier forecasts—due to cost pressures that it expects will persist into the second half of the year. As a result, Molina cut its full-year 2025 adjusted EPS guidance to a range of $21.50 to $22.50, down from at <a href="https://www.benzinga.com/pressreleases/25/04/b44964747/molina-healthcare-reports-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">least $24.50</a> previously. The new forecast reflects a consolidated pre-tax margin just under 4%, at the low end of the company's long-term target.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46238442/jim-cramer-on-centenes-40-crash-fewer-aca-signups-sicker-patients-pulled-guidance-and-major-earnings-hit-trigger-selloff-this-is-horrifying" target="_blank" rel="noreferrer noopener">Jim Cramer On Centene&#8217;s 40% Crash: Fewer ACA Signups, Sicker Patients, Pulled Guidance And Major Earnings Hit Trigger Selloff: &#8216;This Is Horrifying&#8217;</a>
&#8220;The short-term earnings pressure we are experiencing results from what we believe to be a temporary dislocation between premium rates and medical cost trend, which has recently accelerated,&#8221; said CEO Joseph Zubretsky. &#8220;As we are still performing near our long-term target ranges, nothing, including the potential impacts of the budget bill, has changed our outlook for the long-term performance of the business.&#8221;
On Wednesday, Centene Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) withdrew its 2025 GAAP and adjusted diluted EPS guidance, stemming from its initial review of 2025 industry data from Wakely, <a target="_blank" href="https://www.benzinga.com/markets/guidance/25/07/46209736/centene-withdraws-2025-guidance-shares-dive" rel="noreferrer noopener">an independent actuarial firm</a>.
Price Action: MOH stock is up 1.64% at $243.50 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46240012/obama-warns-16-million-americans-could-lose-health-care-as-gop-pushes-trumps-big-beautiful-bill-with-deep-medicaid-cuts" target="_blank" rel="noreferrer noopener">Obama Warns 16 Million Americans Could Lose Health Care As GOP Pushes Trump&#8217;s &#8216;Big Beautiful Bill&#8217; With Deep Medicaid Cuts</a></li>
</ul>
Image: Shutterstock

Guidance

Molina Healthcare Says Higher Medical Cost Trends Bite, Cuts Profit Guidance

MOH stock has given up its prior loss. Molina shares were trading lower after the company guided Q2 EPS to $5.50 vs the $6.21 estimate and cut its full-year EPS outlook amid rising medical costs.

WIIM

Molina shares are trading lower after the company guided Q2 EPS to $5.50 vs the $6.21 estimate and cut its full-year EPS outlook amid rising medical costs.

Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) today announced preliminary financial results for the second quarter of 2025 and updated its full year 2025 adjusted earnings per share guidance. The Company's announcement of preliminary results was driven by recent market dynamics and off-cycle disclosures from others in the managed health care sector.
The Company now expects its second quarter 2025 adjusted earnings to be approximately $5.50 per share(1), which is modestly below its prior expectations. This preliminary result reflects medical cost pressures in all three lines of business. The Company expects these medical cost pressures to continue into the second half of the year. As a result, the Company now expects its full year 2025 adjusted earnings to be in the range of $21.50 to $22.50 per share(1), reflecting a consolidated pre-tax margin of just under 4%, the low-end of its long-term guidance range.

Molina Sees Q2 EPS at $5.50 Vs $6.21 Est, Cuts Full-Year EPS Outlook to $21.50–$22.50 (Prior $24.50) Amid Rising Medical Costs

These ten large-cap stocks were the worst performers in the holiday-shortened week. Are they a part of your portfolio?
<ol class="wp-block-list">
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) stock fell 37.82% amid a sharp selloff after it withdrew its 2025 <a href="https://www.benzinga.com/node/46209736" target="_blank" rel="noreferrer noopener">GAAP and adjusted EPS guidance</a>. Several analysts downgraded the stock and lowered <a href="https://www.benzinga.com/quote/CNC/analyst-ratings" target="_blank" rel="noreferrer noopener">their price forecasts</a>.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock declined 17.69% amid a broader selloff in health insurance stocks following Centene&#8217;s <a href="https://www.benzinga.com/node/46209736" target="_blank" rel="noreferrer noopener">withdrawal of forward guidance</a>.</li>
<li>Circle Internet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) stock plunged 11.64% amid a pullback after recent highs. Several analysts <a href="https://www.benzinga.com/quote/CRCL/analyst-ratings" target="_blank" rel="noreferrer noopener">also initiated ratings on the stock</a>.</li>
<li>Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) stock dipped 10.78% after the company <a href="https://www.benzinga.com/node/46186497" target="_blank" rel="noreferrer noopener">priced an upsized</a> $650 million debt offering due 2030, $250 million more than initially planned.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) stock lowered 9.92% amid a pullback after recent highs.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) stock fell 9.6% after the company announced <a href="https://www.benzinga.com/node/46183842" target="_blank" rel="noreferrer noopener">a proposed $750 million common stock</a> offering and $600 million in convertible notes to repay debt and expand manufacturing.</li>
<li>Antero Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) stock declined 8.88% amid concerns that OPEC+ members may increase oil output, putting pressure on crude prices.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) stock dropped 8.61% after the company reportedly decided to freeze electricity rates for Q3.</li>
<li>Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) stock lost 8.37% amid pressure on energy names due to speculation around an OPEC+ production hike.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) stock decreased 7.37% after it <a href="https://www.benzinga.com/node/46190208" target="_blank" rel="noreferrer noopener">reported a 24.1% year-over-year drop</a> in June deliveries. The broader U.S.-listed Chinese stock sector was also under pressure due to tariff uncertainty as President Trump signaled he may not extend the 90-day tariff pause beyond July 9.</li>
</ol>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46265728/nike-datadog-and-snap-are-among-top-11-large-cap-gainers-last-week-june-30-july-4-are-the-others-in-your-portfolio">NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by Robert Way via Shutterstock

ASTS

AVAV

CRCL

Circle Internet, Centene And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 30-July 4): Are The Others In Your Portfolio?

Shares of managed care provider Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) dropped over 40% on Wednesday, marking the worst single-day performance in the company's history.
Check out the current price of&nbsp;<a href="https://www.benzinga.com/quote/CNC" target="_blank" rel="noreferrer noopener">CNC stock here.</a>
What Happened: On CNBC&#8217;s Mad Money, Jim Cramer referred to the collapse as &#8220;a huge hit,&#8221; resulting from a combination of factors such as weak Affordable Care Act enrollments, an actuarial report pointing to sicker patients, and the company&#8217;s decision to <a href="https://www.benzinga.com/markets/guidance/25/07/46209736/centene-withdraws-2025-guidance-shares-dive">pull its 2025 outlook</a>.
&#8220;Companies make forecasts, they&#8217;re supposed to try and beat them,&#8221; Cramer says, however, &#8220;they rarely pull them.&#8221;
According to Cramer, Centene disclosed data from an independent actuarial firm covering 22 of the 29 states where it operates ACA exchange plans.
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46195080/doj-dismantles-14-billion-healthcare-fraud-scheme-in-largest-ever-crackdown-impacting-over-1-million-americans">DOJ Dismantles $14 Billion Healthcare Fraud Scheme In Largest-Ever Crackdown, Impacting Over 1 Million Americans</a>
The findings showed that overall marketplace enrollment growth was lower than expected and that those who did enroll were in poorer health than projected, a combination that significantly affects the company's bottom line, thus prompting the company to pull its guidance.
As a result, the company now expects a $1.8 billion reduction in its projected risk adjustment revenue from the federal government. This drop is expected to slash its 2025 earnings by $2.75 per share.
&#8220;This is horrifying,&#8221; Cramer said, referring to the sharp revision in Centene&#8217;s EPS, from $7.25 per share projected earlier. &#8220;We&#8217;re talking about a 35% to 40% hit to their numbers,&#8221; Cramer says, &#8220;no wonder the stock was eviscerated.&#8221;
Why It Matters: Centene&#8217;s decision to withdraw its guidance, citing the independent actuarial report, led to a sector-wide selloff on Wednesday. 
All of Centene&#8217;s peers and competitors in the managed care business, such as Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), among others, all falling in tandem during the day. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stocks / ETFs</td>
<td class="has-text-align-center" data-align="center">1 Day</td>
<td class="has-text-align-center" data-align="center">Year-To-Date</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>)</td>
<td class="has-text-align-center" data-align="center">-40.37%</td>
<td class="has-text-align-center" data-align="center">-44.17%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)</td>
<td class="has-text-align-center" data-align="center">-21.97%</td>
<td class="has-text-align-center" data-align="center">-16.79%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)</td>
<td class="has-text-align-center" data-align="center">-11.50%</td>
<td class="has-text-align-center" data-align="center">-4.26%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td class="has-text-align-center" data-align="center">-5.70%</td>
<td class="has-text-align-center" data-align="center">-39.04%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td class="has-text-align-center" data-align="center">-4.19%</td>
<td class="has-text-align-center" data-align="center">+16.72%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">iShares US Healthcare Providers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHF#NYSE">IHF</a>)</td>
<td class="has-text-align-center" data-align="center">-6.27%</td>
<td class="has-text-align-center" data-align="center">-3.16%</td>
</tr>
</tbody>
</table>
</figure>
This comes amid a potential amendment in the Affordable Care Act, which could lead to an additional $313 billion in <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46163659/senate-republicans-propose-313-billion-cut-in-medicaid-spending-in-trumps-big-beautiful-bill">spending cuts</a> by blocking able-bodied adults without dependent children in Medicaid expansion states from receiving the enhanced 9-to-1 Federal Medical Assistance Percentage (FMAP).
Insurers have also <a href="https://www.benzinga.com/personal-finance/tax/25/06/46012776/brace-for-higher-healthcare-premiums-in-2026-as-insurers-blame-trumps-tariffs-in-filings-to-regulators-report">warned of higher premiums</a> in 2026, placing the blame on President Donald Trump&#8217;s tariffs, which are expected to increase the cost&nbsp;of prescription drugs, medical devices,&nbsp;and other medical products and&nbsp;services.
Price Action: Shares of Centene dropped 40.37% on Wednesday, closing at $33.78, but are up 1.10% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="143" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-1024x143.png" alt="" class="wp-image-971299" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-1024x143.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-300x42.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-768x107.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM.png 1532w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Centene scores well on Value and Growth, but has an unfavorable price trend in the short, medium and long term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights on the stock, as well as its peers and competitors in the managed care space.
Photo courtesy: katz / Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/06/46166087/mark-cuban-slams-insurers-over-high-deductibles-urges-josh-hawley-to-change-the-game-with-two-part-plan">Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To &#8216;Change The Game&#8217; With Two-Part Plan</a></li>
</ul>

iShares Dow Jones US Health Care Provides Index Fund

Jim Cramer On Centene's 40% Crash: Fewer ACA Signups, Sicker Patients, Pulled Guidance And Major Earnings Hit Trigger Selloff: 'This Is Horrifying'

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 82.6% to $2.21 during Wednesday's regular session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock moved upwards by 49.15% to $1.76. The market value of their outstanding shares is at $3.2 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares moved upwards by 40.9% to $14.88. The market value of their outstanding shares is at $53.9 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock increased by 31.34% to $4.4. The company's market cap stands at $63.7 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares moved upwards by 27.93% to $10.26. The market value of their outstanding shares is at $89.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares moved upwards by 25.39% to $0.69. The company's market cap stands at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares decreased by 39.6% to $34.19 during Wednesday's regular session. The market value of their outstanding shares is at $28.1 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock decreased by 38.44% to $1.26. The company's market cap stands at $8.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 27.37% to $10.61. The company's market cap stands at $7.2 billion. As per the news, the H1 earnings report came out 2 days ago. </li>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock declined by 25.82% to $0.96. The market value of their outstanding shares is at $80.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 20.43% to $0.27. The market value of their outstanding shares is at $7.9 million. </li>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares declined by 20.18% to $244.5. The market value of their outstanding shares is at $16.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTSO

CYCC

EYEN

LIXT

MBIO

NTHI

NTRB

SONN

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday.
The Dow traded down 0.10% to 44,450.62 while the NASDAQ gained 0.78% to 20,360.92. The S&amp;P 500 also rose, gaining, 0.25% to 6,213.50.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46218048/how-to-earn-500-a-month-from-microsoft-stock-4">How To Earn $500 A Month From Microsoft Stock</a>
Leading and Lagging Sectors Information technology shares jumped by 1% on Wednesday.
In trading on Wednesday, utilities stocks fell by 1.3%.
Top Headline 
U.S. crude oil inventories increased by 3.845 million barrels in the week ended June 27, versus market estimates of a 2 million barrel decline.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares shot up 15% to $21.27 after announcing a key infrastructure win in Ontario.</li>
<li>Shares of Mogo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) got a boost, surging 105% to $2.4800 after the company announced a $50 million bitcoin treasury authorization.</li>
<li>The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) shares were also up, gaining 18% to $55.58 after the company posted stronger-than-expected results for the third quarter.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares dropped 15% to $17.49 after Barclays initiated coverage with an Underweight rating and announced a price target of $17.</li>
<li>Shares of Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) were down 18% to $250.80. Shares of health insurance stocks traded lower in sympathy with Centene, which withdrew its 2025 guidance.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) was down, falling 38% to $34.45 after the company withdrew its previous 2025 GAAP and adjusted diluted EPS guidance, including the underlying guidance elements.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $66.44 while gold traded up 0.1% at $3,354.00.
Silver traded up 0.7% to $36.635 on Wednesday, while copper rose 1.6% to $5.1820.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.13%, while Spain's IBEX 35 Index rose 0.35%. London's FTSE 100 fell 0.24%, Germany's DAX 40 gained 0.51% and France's CAC 40 gained 1.06% during the session.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei dipping 0.56%, China's Shanghai Composite falling 0.09% and India's BSE Sensex falling 0.34%.
Economics
<ul class="wp-block-list">
<li>U.S.-based employers announced job cuts of 47,999 in June versus 93,816 in the previous month and 48,786 in the year-ago period.</li>
<li>The volume of mortgage applications increased by 2.7% from the previous week during the last week of June.</li>
<li>U.S. crude oil inventories increased by 3.845 million barrels in the week ended June 27, versus market estimates of a 2 million barrel decline.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a> </li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

Intraday Update

MOGO

Crude Oil Gains 1.5%; Greenbrier Shares Spike Higher

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) fell sharply in today's pre-market trading after the health<a href="https://www.benzinga.com/quote/CNC"> care company withdrew its guidance for 2025.</a>
Centene withdrew its previous 2025 earnings guidance and all underlying guidance elements based on the company's preliminary interpretation of marketplace data from the independent actuarial firm Wakely.
Centene shares dipped 27.7% to $40.94 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) tumbled 9% to $278.89 in pre-market trading.</li>
<li>BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) dipped 8.8% to $15.37 in pre-market trading after the company lowered its FY25 revenue guidance from $2.75–$2.84 billion to $2.68–$2.73 billion.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares fell 8.3% to $18.75 in pre-market trading after dipping 5% on Tuesday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $11.22 in pre-market trading. Mesoblast shares gained 11% on Tuesday after the company announced it is targeting an accelerated FDA approval for its heart failure drug Revascor.</li>
<li>ArriVent BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) fell 5.4% to $19.76 in pre-market trading as the company announced the pricing of $75 million public offering of common stock and pre-funded warrants.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 4.6% to $20.05 in pre-market trading after the company announced plans for a $100 million convertible notes offering.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AVBP

DFDV

MESO

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of health insurance stocks are trading lower in sympathy with Centene, which withdrew its 2025 guidance.

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 8.06% on an annualized basis producing an average annual return of 20.52%. Currently, Molina Healthcare has a market capitalization of $14.91 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $16,670.36 today based on a price of $275.02 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751406310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 15 Years

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/" title="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>
&nbsp;

ALHC

CLOV

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 7.54% on an annualized basis producing an average annual return of 19.56%. Currently, Molina Healthcare has a market capitalization of $15.87 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $14,429.86 today based on a price of $292.83 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750082419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and lowers the price target from $351 to $347.

Comments

Molina Healthcare

Interés en corto

Molina Healthcare (NYSE:MOH) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL